» Articles » PMID: 22069638

Differential Cell Sensitivity Between OTA and LPS Upon Releasing TNF-α

Overview
Journal Toxins (Basel)
Publisher MDPI
Specialty Toxicology
Date 2011 Nov 10
PMID 22069638
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The release of tumor necrosis factor α (TNF-α) by ochratoxin A (OTA) was studied in various macrophage and non-macrophage cell lines and compared with E. coli lipopolysaccharide (LPS) as a standard TNF-α release agent. Cells were exposed either to 0, 2.5 or 12.5 µmol/L OTA, or to 0.1 µg/mL LPS, for up to 24 h. OTA at 2.5 µmol/L and LPS at 0.1 µg/mL were not toxic to the tested cells as indicated by viability markers. TNF-α was detected in the incubated cell medium of rat Kupffer cells, peritoneal rat macrophages, and the mouse monocyte macrophage cell line J774A.1: TNF-α concentrations were 1,000 pg/mL, 1,560 pg/mL, and 650 pg/mL, respectively, for 2.5 µmol/L OTA exposure and 3,000 pg/mL, 2,600 pg/mL, and 2,115 pg/mL, respectively, for LPS exposure. Rat liver sinusoidal endothelial cells, rat hepatocytes, human HepG2 cells, and mouse L929 cells lacked any cytokine response to OTA, but showed a significant release of TNF-α after LPS exposure, with the exception of HepG2 cells. In non-responsive cell lines, OTA lacked both any activation of NF-κB or the translocation of activated NF-κB to the cell nucleus, i.e., in mouse L929 cells. In J774A.1 cells, OTA mediated TNF-α release via the pRaf/MEK 1/2-NF-κB and p38-NF-κB pathways, whereas LPS used pRaf/MEK 1/2-NF-κB, but not p38-NF-κB pathways. In contrast, in L929 cells, LPS used other pathways to activate NF-κB. Our data indicate that only macrophages and macrophage derived cells respond to OTA and are considered as sources for TNF-α release upon OTA exposure.

Citing Articles

Risk assessment of ochratoxin A in food.

Schrenk D, Bodin L, Chipman J, Del Mazo J, Grasl-Kraupp B, Hogstrand C EFSA J. 2023; 18(5):e06113.

PMID: 37649524 PMC: 10464718. DOI: 10.2903/j.efsa.2020.6113.


Mechanoregulation of Osteoclastogenesis-Inducing Potentials of Fibrosarcoma Cell Line by Substrate Stiffness.

Tiskratok W, Yamada M, Watanabe J, Pengyu Q, Kimura T, Egusa H Int J Mol Sci. 2023; 24(10).

PMID: 37240303 PMC: 10219368. DOI: 10.3390/ijms24108959.


Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma.

Zhang Z, Liu J, Xiao M, Zhang Q, Liu Z, Liu M Nano Res. 2022; 16(4):5206-5215.

PMID: 36405984 PMC: 9643898. DOI: 10.1007/s12274-022-5102-z.


A Newly Isolated ANSA176 with the Capability of Alleviating Immune Injury and Inflammation through Efficiently Degrading Ochratoxin A.

Zheng R, Qing H, Ma Q, Huo X, Huang S, Zhao L Toxins (Basel). 2022; 14(8).

PMID: 36006231 PMC: 9415193. DOI: 10.3390/toxins14080569.


Stem cell-mediated delivery of SPIO-loaded gold nanoparticles for the theranosis of liver injury and hepatocellular carcinoma.

Zhao J, Vykoukal J, Abdelsalam M, Recio-Boiles A, Huang Q, Qiao Y Nanotechnology. 2014; 25(40):405101.

PMID: 25211057 PMC: 4414337. DOI: 10.1088/0957-4484/25/40/405101.


References
1.
Sakurai F, Terada T, Yasuda K, Yamashita F, Takakura Y, Hashida M . The role of tissue macrophages in the induction of proinflammatory cytokine production following intravenous injection of lipoplexes. Gene Ther. 2002; 9(16):1120-6. DOI: 10.1038/sj.gt.3301784. View

2.
Arditi M, Zhou J, DORIO R, Rong G, Goyert S, Kim K . Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14. Infect Immun. 1993; 61(8):3149-56. PMC: 280982. DOI: 10.1128/iai.61.8.3149-3156.1993. View

3.
Al-Anati L, Petzinger E . Immunotoxic activity of ochratoxin A. J Vet Pharmacol Ther. 2006; 29(2):79-90. DOI: 10.1111/j.1365-2885.2006.00718.x. View

4.
Lentschat A, Karahashi H, Michelsen K, Thomas L, Zhang W, Vogel S . Mastoparan, a G protein agonist peptide, differentially modulates TLR4- and TLR2-mediated signaling in human endothelial cells and murine macrophages. J Immunol. 2005; 174(7):4252-61. DOI: 10.4049/jimmunol.174.7.4252. View

5.
Qureshi S, Lariviere L, Leveque G, Clermont S, Moore K, Gros P . Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med. 1999; 189(4):615-25. PMC: 2192941. DOI: 10.1084/jem.189.4.615. View